Acorda Therapeutics Inc (NASDAQ:ACOR) shareholders are spooked right now after the drug maker confirmed yesterday that enrollment in two long-term safety trials for Parkinson’s asset tozadenant is paused on the heels of 5 deaths from sepsis. In the aftermath, J.P. Morgan analyst Cory Kasimov points to rising pipeline skepticism, cutting his price target.
J.P. Morgan Says Acorda Troubling Parkinson’s Trial Lessens Upside Potential
